AbbVie vs Amgen: Business Model & Financial Comparison 2026
AbbVie · Healthcare / Drug Manufacturers - General·Amgen · Healthcare / Drug Manufacturers - General
Financial Comparison
| Metric | ABBVAbbVie | AMGNAmgen |
|---|---|---|
| Market Cap | $398.49B | $198.26B |
| Revenue (TTM) | $61.16B | $36.75B |
| Revenue Growth | 10.0% | 8.6% |
| Gross Margin | 71.6% | 70.8% |
| Operating Margin | 34.1% | 30.5% |
| Net Margin | 6.9% | 21.0% |
| Return on Equity | 6225.0% | 106.1% |
| P/E (Trailing) | 95.1x | 25.8x |
| P/E (Forward) | 14.0x | 15.8x |
| Free Cash Flow | $18.34B | $7.50B |
| Cash | $5.26B | $9.13B |
| Total Debt | $68.40B | $55.44B |
Data sourced from Yahoo Finance. Green highlights indicate better performance for that metric. Use the interactive tool for real-time data.
Business Model Comparison
AbbVie
AbbVie Inc. stands as a leading company in Healthcare. Generating $61.16 billion in annual revenue (growing 10.0% year-over-year) and carrying a market capitalization of $410.83 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, AbbVie Inc. continues to execute on a multi-year strategic vision that balances growth investment wit…
Full AbbVie analysis →Amgen
Amgen Inc. stands as a leading company in Healthcare. Generating $36.75 billion in annual revenue (growing 8.6% year-over-year) and carrying a market capitalization of $198.16 billion, the company has cemented its position as a foundational player in the global Drug Manufacturers - General landscape. Under the leadership of its leadership team, Amgen Inc. continues to execute on a multi-year strategic vision that balances growth investment with s…
Full Amgen analysis →SWOT Analysis Comparison
Strengths
AbbVie
- With a market capitalization of $410.83B, AbbVie Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access that sma
- AbbVie Inc.'s gross margin of 71.6% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 34.1% demonstrates disciplin
- A return on equity of 6225.0% demonstrates that AbbVie Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Amgen
- With a market capitalization of $198.16B, Amgen Inc. is one of the largest companies in its sector, providing the scale advantages of brand recognition, supplier leverage, and capital access that smal
- Amgen Inc.'s gross margin of 70.8% is well above industry averages, reflecting pricing power, operational efficiency, or a high-value product mix. The operating margin of 30.5% demonstrates discipline
- A return on equity of 106.1% demonstrates that Amgen Inc. generates strong returns from shareholder capital, a hallmark of companies with durable competitive advantages.
Weaknesses
AbbVie
- In the Drug Manufacturers - General sector, larger competitors with greater economies of scale can exert pricing pressure and outspend AbbVie Inc. on marketing, R&D, and distribution — limiting the co
- Revenue concentration in core markets or customer segments creates vulnerability to localized downturns, regulatory changes, or shifts in customer preferences. Diversification remains an ongoing strat
Amgen
- With a debt-to-equity ratio of 640.3, Amgen Inc. carries significant debt relative to equity. While manageable given its cash flow, elevated leverage limits financial flexibility and increases vulnera
Opportunities
AbbVie
- AbbVie Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this env
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for AbbVie
- With $5.26B in cash and strong free cash flow generation, AbbVie Inc. is well-positioned to pursue strategic acquisitions that expand its capabilities, customer base, or geographic reach.
Amgen
- Amgen Inc. operates in the Drug Manufacturers - General segment of the broader Healthcare sector, which represents a $12 trillion global healthcare market by 2030. Even modest share gains in this envi
- Emerging markets — particularly India (1.4B people, rapidly growing middle class), Southeast Asia (700M people), and Sub-Saharan Africa — represent significant untapped addressable markets for Amgen I
- Earnings growth of 112.1% YoY demonstrates Amgen Inc.'s ability to convert revenue growth into shareholder value. Analysts project continued earnings expansion driven by operating leverage as fixed co
Threats
AbbVie
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. AbbVie Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scen
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on AbbVie Inc.'s busin
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Amgen
- Global economic slowdowns, inflation, or rising interest rates can reduce consumer and enterprise spending. Amgen Inc.'s revenue is not fully insulated from macroeconomic cycles, and a recession scena
- Increasing government regulation — particularly data privacy laws (GDPR, CCPA), antitrust enforcement, and trade restrictions — poses compliance costs and potential restrictions on Amgen Inc.'s busine
- Competition for skilled technology, engineering, and management talent remains intense. High employee turnover or inability to attract top talent could slow innovation and execution — particularly cri
Compare any 2–4 companies with live data
The interactive comparison tool lets you select any companies, see real-time metrics, and export a side-by-side report.
Open Comparison ToolAbbVie vs Amgen: FAQ
- Is AbbVie bigger than Amgen?
- By market capitalization, AbbVie is larger at $398.49B vs Amgen's $198.26B.
- Which has better profit margins — AbbVie or Amgen?
- Amgen has higher net profit margins (21.0%) compared to AbbVie (6.9%). Gross and operating margins are compared in the table above.
- What sectors do AbbVie and Amgen operate in?
- AbbVie operates in the Healthcare sector (Drug Manufacturers - General). Amgen operates in the Healthcare sector (Drug Manufacturers - General).
- How does AbbVie's revenue compare to Amgen's?
- AbbVie generates $61.16B in annual revenue (TTM) while Amgen generates $36.75B. AbbVie is the larger company by revenue as of 2026.